Cancer cells can treat tumors

Cancer cells can treat tumors.
New probe suggests that many cancer cells are equipped with a sympathetic of suicide pill: a protein on their surfaces that gives them the power to send an "eat me" outstanding to immune cells. The challenge now, the researchers say, is to appearance out how to coax cancer cells into emitting the unique rather than a dangerous "don't eat me" signal female. A research published online Dec 22 2010 in Science Translational Medicine reports that the cells turn out the enticing "eat me" announce by displaying the protein calreticulin.

But another molecule, called CD47, allows most cancer cells to evade down by sending the opposite signal: "Don't eat me". In earlier research, Stanford University School of Medicine scientists found that an antibody that blocks CD47 - turning off the important - could worker pluck cancer, but mysteries remained. "Many conventional cells in the body have CD47, and yet those cells are not acted upon by the anti-CD47 antibody," Mark Chao, a Stanford graduate follower and the study's lead author, said in a university news release.

And "At that time, we knew that anti-CD47 antibody curing selectively killed only cancer cells without being toxic to most stable cells, although we didn't skilled in why". Now, the new research has shown that calreticulin exists in a category of cancers, including some types of leukemia, non-Hodgkin's lymphoma and bladder, intelligence and ovarian cancers.

So "This analysis demonstrates that the reason that blocking the CD47 'don't nourishment me' signal works to kill cancer is that leukemias, lymphomas and many jammed tumors also display a calreticulin 'eat me' signal," Dr Irving Weissman, overseer of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and a co-principal investigator of the study, said in the release. "The delve into also shows that most sane room populations don't display calreticulin and are, therefore, not depleted when we display them to a blocking anti-CD47 antibody".

The next bow out is to understand how calreticulin works. "We want to know how it contributes to the illness process and what is happening in the cell that causes the protein to change to the cell surface," Dr Ravindra Majeti, an helpmeet professor of hematology and study co-principal investigator, said in the release stallion xl cassino before and after. "Any of these mechanisms come forward potential new ways to deal with the disease by interfering with those processes".